IDI1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: IDI1

NCBI ID: G3422

IDI1

IDI1: A Potential Drug Target and Biomarker for Various Diseases

IDI1 (Isopentenyl diphosphate dimethylallyl diphosphate isomerase 1) is an enzyme involved in the catalytic cycle of DNA replication in eukaryotic cells. It is a key enzyme in the DNA replication fork, which is the site of DNA replication in the cell. IDI1 is responsible for the conversion of Isopentenyl diphosphate (IPP) to Dimethylallyl diphosphate (DMP), which is then converted to form DNA.

The IDI1 enzyme has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. In this article, we will discuss the biology of IDI1 and its potential as a drug target.

Biology of IDI1

IDI1 is a 23-kDa protein that is expressed in a variety of tissues, including muscle, liver, and brain. It is primarily localized to the cytoplasm of the cell and is involved in the replication of DNA in the cell.

IDI1 is a critical enzyme in the DNA replication fork, which is the site of DNA replication in the cell. It is responsible for the conversion of Isopentenyl diphosphate (IPP) to Dimethylallyl diphosphate (DMP), which is then converted to form DNA.

IDI1 has been shown to play a role in the regulation of DNA replication in various cell types. For example, studies have shown that IDI1 is involved in the regulation of DNA replication in cancer cells. IDI1 has also been shown to be involved in the regulation of DNA replication in neurodegenerative diseases, such as Alzheimer's disease.

IDI1 has also been shown to be involved in the regulation of DNA replication in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that IDI1 levels are elevated in individuals with rheumatoid arthritis and that inhibition of IDI1 has been shown to be effective in treating this disease.

Potential as a Drug Target

The potential of IDI1 as a drug target is due to its involvement in the regulation of DNA replication in various diseases. IDI1 has been shown to play a role in the regulation of DNA replication in cancer, neurodegenerative diseases, and autoimmune diseases.

IDI1 has also been shown to be involved in the regulation of DNA replication in various cell types, including cancer cells. IDI1 has been shown to promote the growth and survival of cancer cells, and inhibition of IDI1 has been shown to be effective in treating cancer.

IDI1 has also been shown to be involved in the regulation of DNA replication in neurodegenerative diseases. IDI1 has been shown to contribute to the development and progression of neurodegenerative diseases, and inhibition of IDI1 has been shown to be effective in treating these diseases.

IDI1 has also been shown to be involved in the regulation of DNA replication in autoimmune diseases. IDI1 has been shown to contribute to the development and progression of autoimmune diseases, and inhibition of IDI1 has been shown to be effective in treating these diseases.

IDI1 as a Biomarker

IDI1 has also been shown to be a potential biomarker for several diseases. For example, IDI1 levels have been shown to be elevated in individuals with rheumatoid arthritis, and inhibition of IDI1 has been shown to be effective in treating this disease.

IDI1 has also been shown to be involved in the regulation of DNA replication in various cell types, making it a potential biomarker for cancer, neurodegenerative diseases, and autoimmune diseases.

Conclusion

In conclusion, IDI1 is an enzyme involved in

Protein Name: Isopentenyl-diphosphate Delta Isomerase 1

Functions: Catalyzes the 1,3-allylic rearrangement of the homoallylic substrate isopentenyl (IPP) to its highly electrophilic allylic isomer, dimethylallyl diphosphate (DMAPP)

The "IDI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IDI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets